

Procurement, Commissioning & Facilities
NHS National Services Scotland
National Distribution Centre
2 Swinhill Avenue
Canderside
Larkhall
ML9 2QX



Telephone 01698 794400
Fax 01698 794401
[RNID Typetalk; 18001 01698 794400/794410](mailto:nss.pcf-foi@nhs.scot)

Date: 24 May 2022
Our ref: K: FOI/Ref: 2022-000098
Direct Line: 0131 275 6807
Email: nss.pcf-foi@nhs.scot

Dear [REDACTED]

Freedom of Information Reference: FOI-2022-000098 volume of coagulation factor distributed to NHS Scotland

I refer to your freedom of information request that we received on 26 April 2022 requesting the following information.

I, [REDACTED], would like to submit an FOI request for the volume of coagulation factor (in IU or mg) distributed to NHS Scotland Hospitals in each month from January 2022 to March 2022, broken down by-product (see below). If the volume by brand is not available, I would like to request the number of vials distributed by brand. If possible, I would also like the number of patients by brand. Thank you very much for your time and assistance:

- Hemlibra
- Esperoct
- Adynovi
- Elocta
- NovoEight
- Advate
- ReFacto AF
- Nuwiq
- NovoSeven
- FEIBA
- Obizur
- Idelvion
- Refixia
- Alprolix
- BeneFIX
- Replenine
- Rixubis

I can advise you that we have now completed the search of our records and can provide you with the following information:

Usage data is presented in Appendix 1, which is for NHS Scotland secondary care (hospital and homecare usage) detailing the volume of coagulation factor distributed to NHS Scotland, please see below a few points to consider when reviewing the data:



Headquarters

Gyle Square, 1 South Gyle Crescent, EDINBURGH EH12 9EB

Chairperson Keith Redpath
Chief Executive Mary Morgan

- Usage data on the spreadsheet has been separated into secondary care usage and homecare usage. Patients in the first instance are treated in the acute centre and, when stable on their prescribed medication, can get a hospital prescription delivered to their home. The homecare medicine delivery service delivers ongoing medicine supplies and, where necessary, associated care, initiated by the hospital prescriber, direct to the patient's home with their consent.
- The Commercial Medicines Unit (CMU) in NHS England facilitate the allocation of supply to secondary care in NHS Scotland. Hospital usage is not broken down by patient specific prescriptions, therefore, patient numbers are not known. However, patient numbers treated within homecare have been included (by brand).
- The volume by brand has been provided for both care settings.
- There is no usage data for a number of brands detailed in the request as there are no patients on these medicines within NHS Scotland.

I trust you will find the information of assistance and if you require any further information, please do not hesitate to contact me.

If you are unhappy with any aspect of how we have dealt with your request, you can make representations to us asking us to review the handling of your request. Please write to the

Head of Information and Cyber Security
Digital and Security
NHS National Services Scotland
Headquarters
Gyle Square
1 South Gyle Crescent
Edinburgh
EH12 9EB

or at the email address nss.foi@nhs.scot within 40 working days of the date of this correspondence.

If after a review you are still unhappy, you also have the right to apply to the Scottish Information Commissioner, who can be contacted at Kinburn Castle, St Andrews, Fife, KY16 9DS, or via their [online application form](#).

If you have any queries about this letter, please contact me at the above address.

Yours sincerely

